MedTrace Logo

Concomitant LAAC/AF Ablation (Watchman FLX Pro)

NCT07041125 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-09-24

No results posted yet for this study

Summary

This sub-study is a prospective/retrospective, non-randomized, observational, comparative cohorts study, embedded in and expanding on the infrastructure of a real-world AF ablation registry DISRUPT-AF (NCT06335082).

Conditions

  • PFA Ablation and LAAC Procedures

Interventions

DEVICE

Watchman FLX™ Pro device.

Patients eligible for the main DISRUPT-AF Registry with a planned concomitant LAAC procedure using the Watchman FLX™ Pro device.

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Heart Rhythm Clinical and Research Solutions, LLC

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-09-30
Completion
2026-10-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041125 on ClinicalTrials.gov